Vincerx Pharma, Inc. (VINC) Short-Term Debt to Equity

Graphic logo of Vincerx Pharma, Inc. (VINC)

The market dynamics of Vincerx Pharma, Inc. (VINC) securities demonstrate a debt-to-equity ratio of 0.00. The financial potential of Vincerx Pharma, Inc. relies on the future commercialization of ADC drugs following the confirmation of their safety. Leading biochemists, motivated by their personal contribution to science, ensure the project's success. Meanwhile, the company strictly complies with environmental regulations regarding the disposal of laboratory waste and adheres to ethical research standards.

VINC - Vincerx Pharma, Inc. Short-Term Debt to Equity Ratio over the range 07/04/2022 - 05/31/2025

Financial and market metric breakdowns for Vincerx (VINC)

- stock quotes and analyst forecast:
Stock Price Vincerx Pharma, Inc.|VINC - Analyst Consensus Forecast
- market capitalization details:
Market Value Vincerx Pharma Inc.|VINC - Business Value
- balance sheet equity data:
Book Value per Share Vincerx Pharma|VINC - Company Net Assets|Market Capitalization to Book Value Ratio vincerx.com|VINC - Company Assets
- business debt structure and liquidity details:
Debt to Equity Vincerx Pharma, Inc.|VINC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Vincerx Pharma, Inc.|VINC - Aggregate Debt Obligations|Debts to Book Capitalization Vincerx Pharma Inc.|VINC - Company Long-Term Debt|Company Short-Term Debt Vincerx Pharma|Quick Liquidity vincerx.com
- earnings and market ratios statistics:
VINC - Company Net Income
Fundamental valuation:Vincerx Pharma
Signature product of vincerx.com

To minimize liquidity risks, it is critical for investors to monitor the ratio of current liabilities to equity, which allows for an assessment of the company's dependence on short-term borrowing; by analyzing the dynamics of the short-term debt-to-equity structure, one can determine the balance between financial stability and the growth rate of the Vincerx Pharma, Inc. (VINC) ecosystem in the field of targeted toxin delivery for safe oncology therapy.

Competing companies

Short-Term Debt to Capital TGTX|Short-Term Debt to Capital Arcellx Therapeutics (ACLX)|Short-Term Debt to Equity Disc Medicine, Inc. IRON|SNDX: Short-Term Debt to Capital Ratio|Kura Oncology - Short-Term Debt to Capital|ADC Therapeutics S.A. (ADCT) - Short-Term Debt to Equity Ratio|FHTX: Short-Term Debt to Capital|Current Liabilities to Capital Vor Bio Inc. (VOR)|Short-Term Debt to Equity Nkarta Inc.|COEP: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ATNM (Actinium Pharmaceuticals, Inc.)|ESLA (Estrella Immunopharma Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CASI (CASI Pharmaceuticals, Inc.)|Marker Therapeutics Inc - Short-Term Debt to Equity|INAB - Short-Term Debt to Equity|ERNA: Short-Term Debt to Equity|GT Biopharma (GTBP) - Short-Term Debt to Equity|Current Liabilities to Capital Aptose Biosciences (APTO)|Short-Term Debt to Equity Bio-Path|Current Liabilities to Capital MEI Pharma Corporation MEIP